CNS tumours
Invited discussant abstracts 326PD, 327PD and 328PD
Date
08 Oct 2016Session
CNS tumoursPresenters
Andreas HottingerAuthors
A. HottingerAuthor affiliations
- Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3798 - The first study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed or refractory low-grade gliomas
Presenter: Mark Kieran
Session: CNS tumours
Resources:
Abstract
2123 - Clinical risk or molecular risk: What matters in low grade gliomas? A study from the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Presenter: Enrico Franceschi
Session: CNS tumours
Resources:
Abstract
3734 - ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study
Presenter: Shou-Ching Tang
Session: CNS tumours
Resources:
Abstract
2882 - Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics
Presenter: Ed Schwalbe
Session: CNS tumours
Resources:
Abstract
1309 - Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM)
Presenter: Andrew Lassman
Session: CNS tumours
Resources:
Abstract
2390 - PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma
Presenter: Estelle Bronsart
Session: CNS tumours
Resources:
Abstract
2763 - Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs)
Presenter: Giuseppe Lombardi
Session: CNS tumours
Resources:
Abstract
2078 - Survival of patients with synchronous and metachronous breast cancer and meningioma
Presenter: Catarina Ribeiro
Session: CNS tumours
Resources:
Abstract
2652 - Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)
Presenter: Anna Sophie Berghoff
Session: CNS tumours
Resources:
Abstract
3029 - Phase I/II study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Presenter: Christian Grommes
Session: CNS tumours
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.